Abstract
Background Understanding the interplay between educational attainment and genetic predictors of cardiovascular risk may improve our understanding of mechanisms relating educational attainment to cardiovascular disease.
Methods In up to 320 120 UK Biobank participants of White British ancestry (mean age = 57, female 54%), we created polygenic scores for nine cardiovascular risk factors or diseases: alcohol consumption, body mass index, low-density lipoprotein cholesterol, lifetime smoking behaviour, systolic blood pressure, atrial fibrillation, coronary heart disease, type 2 diabetes and stroke. We estimated whether educational attainment modified genetic susceptibility to these risk factors and diseases.
Results On the additive scale, higher educational attainment reduced genetic susceptibility to higher BMI, smoking, atrial fibrillation and type 2 diabetes, but increased genetic susceptibility to higher LDL-C and higher systolic blood pressure.
On the multiplicative scale, there was evidence that higher educational attainment increased genetic susceptibility to atrial fibrillation and coronary heart disease, but no evidence of effect modification was found for all other considered traits.
Conclusions Educational attainment modifies the genetic susceptibility to some cardiovascular risk factors and diseases. The direction of this effect was mixed across traits considered and differences in associations between the effect of the polygenic score across strata of educational attainment was uniformly small. Therefore, any effect modification by education of genetic susceptibility to cardiovascular risk factors or diseases is unlikely to contribute substantially to the mechanisms driving inequalities in cardiovascular risk.
Key Messages
The role of educational attainment in modifying the effect of polygenic scores for a wide range of cardiovascular risk factors or diseases has not previously been studied
We explore whether educational attainment modifies the effects of polygenic susceptibility to alcohol consumption, body mass index, low-density lipoprotein cholesterol, lifetime smoking behaviour, systolic blood pressure, atrial fibrillation, coronary heart disease, type 2 diabetes and stroke
Effect modification by education was observed for some cardiovascular polygenic scores, but not all.
Effects were not always in the hypothesised direction and were dependent on the scale of analysis.
Modification of the effect of genetic susceptibility to cardiovascular risk factors or cardiovascular disease by educational attainment is unlikely to contribute substantially to the mechanisms driving inequalities in cardiovascular risk.
Competing Interest Statement
DG is employed part-time by Novo Nordisk. The remaining authors have no conflicts of interest to declare.
Funding Statement
No funding body has influenced data collection, analysis or its interpretations. This research was conducted using the UK Biobank Resource using application 10953. ARC is funded by the UK Medical Research Council Integrative Epidemiology Unit, University of Bristol (MC_UU_00011/1). ARC, GDS, AET, NMD and LDH work in a unit that receives core funding from the UK Medical Research Council and University of Bristol (MC_UU_00011/1). DG is supported by the British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London, and a National Institute for Health Research Clinical Lectureship (CL-2020-16-001) at St. George's, University of London. AET and GDS are supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at University Hospitals Bristol NHS Foundation and the University of Bristol. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. NMD is supported by a Norwegian Research Council Grant number 295989. LDH is funded by a Career Development Award from the UK Medical Research Council (MR/M020894/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used in this study has been archived with the UK Biobank study and was carried out under approved project 10953
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding No funding body has influenced data collection, analysis or its interpretations. This research was conducted using the UK Biobank Resource using application 10953. ARC is funded by the UK Medical Research Council Integrative Epidemiology Unit, University of Bristol (MC_UU_00011/1). ARC, GDS, AET, NMD and LDH work in a unit that receives core funding from the UK Medical Research Council and University of Bristol (MC_UU_00011/1). DG is supported by the British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London, and a National Institute for Health Research Clinical Lectureship (CL-2020-16-001) at St. George’s, University of London. AET and GDS are supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at University Hospitals Bristol NHS Foundation and the University of Bristol. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. NMD is supported by a Norwegian Research Council Grant number 295989. LDH is funded by a Career Development Award from the UK Medical Research Council (MR/M020894/1).
Disclosures DG is employed part-time by Novo Nordisk. The remaining authors have no conflicts of interest to declare.
Transparency statement: ARC affirms that the manuscript is an honest, accurate and transparent account of the study being reported and no important aspects of the study have been omitted.
Availability of Data and materials The data used in this study has been archived with the UK Biobank study. The analysis code used is available at github.com/alicerosecarter/gxe_cv_riskfactors.
Data Availability
The data used in this study has been archived with the UK Biobank study and was carried out under approved project 10953. The analysis code used is available at github.com/alicerosecarter/gxe_cv_riskfactors.
